# EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

> **NCT01040832** · PHASE2 · COMPLETED · sponsor: **EMD Serono** · enrollment: 107 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** EMD 1201081

## Key facts

- **NCT ID:** NCT01040832
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-01
- **Final completion:** —
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01040832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01040832, "EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01040832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*